GVS SPA: directors' dealings · Italy · Consob

About GVS SPA

GVS S.p.A. is an Italian industrial company listed on Borsa Italiana (FTSE MIB), headquartered in Bologna, Italy. Founded in 1979, GVS has evolved from a supplier of healthcare components into a global specialist in advanced filtration solutions. The company’s strategy is built on innovation, vertical integration, and a “glocal” operating model: close proximity to customers in local markets, supported by a globally distributed manufacturing and commercial network. Today, GVS serves several end markets, primarily Healthcare & Life Sciences, Energy & Mobility, and Health & Safety. These are highly regulated industries where product performance, reliability, and compliance are critical. Its portfolio includes filtration solutions and components used in medical devices, laboratory analysis, transfusion medicine, safety applications, mobility-related systems, and a broad range of industrial uses. The group emphasizes product development, process innovation, and proprietary know-how, supported by R&D capabilities, patents, and integrated production processes from design through delivery. From a competitive standpoint, GVS is positioned among the world’s leading manufacturers of advanced filtration solutions for critical applications. Its differentiation lies in its specialization, its ability to serve demanding technical applications, and its international footprint. The group operates manufacturing sites in Italy, the United Kingdom, Brazil, the United States, China, Mexico, Romania, and Puerto Rico, alongside a wide network of commercial offices worldwide. This geographic diversification supports customer proximity and reduces reliance on any single market. Recent developments are important for investors. In January 2025, GVS completed the acquisition of Haemonetics’ whole blood business, strengthening its exposure to transfusion medicine and broadening its healthcare offering. Management also highlighted in first-quarter 2025 disclosures that the integration of this business should contribute to revenue ramp-up, while the group continues industrial efficiency initiatives. Reported results indicate improving profitability and ongoing attention to balance sheet discipline. Overall, GVS combines defensive exposure to healthcare and laboratory end markets with international growth potential and an execution-focused industrial profile.